A comparative study on the therapeutic effects of Silymarin and Silymarin-Loaded Solid Lipid Nanoparticles on D-GaIN/TNF-α-induced Liver Damage in Balb/c Mice

Food and Chemical Toxicology

Volumn 77, Issue , 2015, Pages 93-100

  Cengiz, Mustafa ^a   Kutlu, H Mehtap ^a   Burukoglu, Dilek D ^b   Ayhanci, Adnan ^b  

^a ANADOLU UNIVERSITY   (Turkey)

^b ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Balb c mice; D GaIN TNF ; Hepatoprotectivity; Hepatotoxicity; Silymarin loaded solid lipid nanoparticle

Indexed keywords

GALACTOSAMINE; SILYMARIN; SOLID LIPID NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; LIPID; NANOPARTICLE; PROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; LIVER PROTECTION; LIVER TOXICITY; MALE; MICROSCOPY; MOUSE; NONHUMAN; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; LIVER; METABOLISM; PARTICLE SIZE;

MUS;

ANIMALS; ANTIOXIDANTS; DRUG DELIVERY SYSTEMS; GALACTOSAMINE; LIPIDS; LIVER; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; PROTECTIVE AGENTS; SILYMARIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921512754     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2014.12.011     Document Type: Article

References (37)

1. Al-Haj N., Rasedee A. Solid lipid nanoparticles preparation and characterization. Sci. Alert 2009, 1:90-93.
2. Angermuller S., Kunstle G., Tiegs G. Pre-apoptotic alterations in hepatocytes of TNF alpha-treated galactosamine-sensitized mice. J. Histochem. Cytochem 1998, 46:1175-1183.
3. Basaga H., Poli G., Tekkaya C., Aras I. Free radical scavenging and anti-oxidative properties of 'silibin' complexes on microsomal lipid peroxidation. Cell Biochem. Funct 1997, 15:27-33.
4. Bourdi M., Masubuchi Y., Reilly T.P., Amouzadeh H.R., Martin J.L., George J.W., et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 2002, 35(2):289-298.
5. Bradham C.A., Plumpe J., Manns M.P., Brenner D.A., Trautwein C. Mechanism of hepatic toxicity. TNF-induced liver injury. Am. J. Physiol 1998, 275(3 Pt1):G387-G392.
6. Decker K., Keppler D. Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev. Physiol. Biochem. Pharmacol 1974, (71):77-106.
7. Demirel M., Yazan Y., Müller R.H., Kiliç F., Bozan B. Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro and nanoparticles. J. Microencapsil 2001, 18(3):359-371.
8. Fintelmann V. Modern phytotherapy and its uses in gastrointestinal conditions. Planta Med 1991, 57:S48-S52.
9. Flora K., Hahn M., Rosen H., Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol 1998, 93:139-143.
10. Gezginci S., Bolkent S. The effect of Z-FA.FMK on D-galactosamine/TNF-α-induced liver injury in mice cell. Biochem. Funct. Cell Biochem. Funct 2007, 25:277-286.
11. Hashimoto K., Minaga W., Yanagi Y. Caspase-dependent apoptosis in fulminant hepatic failure induced bu herpes simplex virus in mice. J. Hepatol 2003, 39(5):773-778.
12. Jaeschke H., Fisher M.A., Lawson J.A., Simmons C.A., Farhood A., Jones D.A. Activation of caspase 3 (CPP32)-like proteases is essential for TNF-alpha-induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. J. Immunol 1998, 160:3480-3486.
13. Koppel D.E. Analysis of macromolecular dispersity in intensity correlation spectroscopy: the method of cumulants. J. Chem. Phys 1972, 57:4814.
14. Kvasnika F., Biba B., Sevcík R., Voldrich M., Krátká J. Analysis of the active components of silymarin. J. Chromatogr. A 2003, 990:239-245.
15. Lee J.I., Hsu B.H., Wu D., Barrett J.S. Separation and characterization of silybin, isosilybin, silydianin and silychristin in milk thistle extract by liquid chromatography-electrospray tandem mass spectrometry. J. Chromatogr. A 2006, 1116:57-68.
16. Leist M., Gantner F., Bohlinger I., Germann P.G., Tiegs G., Wendel A. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J. Immunol 1994, 153:1778-1788.
17. Lorenz D., Lucker P., Mennicke W., Wetzelsberger N. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find. Exp. Clin. Pharmacol 1984, 6:655-661.
18. Madani H., Talebolhosseini M., Asgary S., Naderi G.H. Hepatoprotective activity of Silybum marianum and Cichorium intybus against Thioacetamide in Rat. Pak. J. Nutr 2008, 7(1):172-176.
19. Manna S.K., Mukhopadhyay A., Van N.T. Silymarin suppresses TNF-induced activation of NF-kB, c-Jun N-terminal kinase and apoptosis. J. Immunol 1999, 163:6800-6809.
20. Morio L.A., Chiu H., Sprowless K.A., Zhou P., Heck D.E., Gordon M.K., et al. Distinct roles of tumour necrosis factor- alpha and nitric oxide in acute liver injury induced by carbon tetrachloride in mice. Toxicol. Appl. Pharmacol 2001, 172:44-51.
21. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm 2000, 50:161-177.
22. 4 liver damage. J. Appl. Toxicol 1990, 10(4):275-279.
23. Nitatori T., Sato N., Waguri S., Karasawa Y., Araki H., Shinabai K., et al. Delayed neuronal death in the CA1 pyramidal cell layer of the gerbil hippocampus following transient ischemia is apoptosis. J. Neurosci 1994, 15(2):1001-1011.
24. Numanoglu U., Tarimci N. Characterization of solid lipid nanoparticles (SLNTM) and their pharmaceutical and cosmetic applications. Ankara J. Fac. Pharm 2006, 35(3):211-235.
25. Patel N., Joseph C., Corcoran G.B., Ray S.D. Silymarin modulates doxorubicin- induced oxidative stress, Bcl-xL and p53 expression while preventing apoptotic and necrotic cell death in the liver. Toxicol. Appl. Pharmacol 2000, 245:143-152.
26. Pritchard D.J., Butler W.H. Apoptosis-the mechanism of cell death in dimethylnitrosamine-induced hepatotoxicity. J. Pathol 1989, 158(3):253-260.
27. Provinciali M., Papalini F., Orlando F., Pierpaoli S., Donnini Paolo Morazzoni A., Riva A., et al. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/ neu transgenic mice. Cancer Res 2007, 67:2022-2029.
28. Santosh K., Anshu R., Manjeshwar B. Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Mol. Cancer Ther 2005, 4:207-216.
29. Schulz H., Schurer M., Krumbiegel G., Wachter W., Weyhenmeyer R., Seidel G. The solubility and bioequivalence of silymarin preparations. Arzneimittelforschung 1995, 45:61-64. German.
30. Shi J., Aisaki K., Ikawa Y., Wake K. Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride. Am. J. Pathol 1998, 153(2):515-525.
31. Stachlewitz R.F., Seabra V., Bradford B., Bradham C.A., Rusyn I., Germolec D., et al. Glycine and uridine prevent D-galactosamine hepatotoxicity in the rat: role of Kupffer cells. Hepatology 1999, 29(3):737-745.
32. Takka S., Tursilli R., Bianchi A., Scalia S. Assay of common sunscreen agents in suncare products by high performance liquid chromatography on a cyanopropyl bonded silica column. J. Pharm. Biomed. Anal 2005, 38:250-255.
33. Venkateswarlu V., Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Rel 2004, 95:627-638.
34. Wu J.W., Lin L.C., Hung S.C. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J. Pharm. Biomed. Anal 2007, 45(63):5-641.
35. Wu J.W., Lin L.C., Tsai T.H. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J. Ethnopharmacol 2009, 121:185-193.
36. Zang G.Q., Zhou X.Q., Yu H., et al. Effect of hepatocyte apoptosis induced by TNF-alpha on acute severe hepatitis in mouse models. World J. Gastroenterol 2000, 6:688-692.
37. Zhang H.L., Bai T.C., Yan G.B., Hu Y.J. Solubility of silybin in aqueous poly (vinylpyrrolidone) solution. Fluid Phase Equilibr 2005, 238(2):186-192.